An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Public ClinicalTrials.gov record NCT02398461. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.
Study identification
- NCT ID
- NCT02398461
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2015 (Type not available)
- Primary completion
- Sep 2017 (Actual)
- Completion
- Sep 21, 2017 (Actual)
- Last update posted
- Aug 22, 2018
2015 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Acorda Site #12 | Long Beach | California | 90806 | — |
| Acorda Site #3 | Sacramento | California | 95817 | — |
| Acorda Site #7 | San Francisco | California | 94158 | — |
| Acorda Site #11 | Aurora | Colorado | 80045 | — |
| Acorda Site #16 | Centennial | Colorado | 80112 | — |
| Acorda Site #22 | Chicago | Illinois | 60612 | — |
| Acorda Site #14 | St Louis | Missouri | 63131 | — |
| Acorda Site #19 | Teaneck | New Jersey | 07666 | — |
| Acorda Site #10 | Rochester | New York | 14642 | — |
| Acorda Site #18 | Dallas | Texas | 75390-8508 | — |
| Acorda Site #2 | Seattle | Washington | 98101 | — |
| Acorda Site #6 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02398461, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02398461 live on ClinicalTrials.gov.